Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into
Yingzhi Chen1, Meng Zhang1, Hongyue Jin2
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China; University of Chinese Academy of Sciences, 19A Yuquan Rd, Beijing 100049, China.
Abstract:
Poor tumor-targeted and cytoplasmic delivery is a bottleneck for protein toxin-based cancer therapy. Ideally, a protein toxin drug should remain stealthy in circulation for prolonged half-life and reduced side toxicity, but turn activated at tumor. PEGylation is a solution to achieve the first goal, but creates a hurdle for the second because PEG rejects interaction between the drugs and tumor cells therein. Such PEG dilemma is an unsolved problem in protein delivery. Herein proposed is a concept of turning PEG dilemma into prodrug-like feature. A site-selectively PEGylated, gelatinase-triggered cell-penetrating trichosanthin protein delivery system is developed with three specific aims. The first is to develop an intein-based ligation method for achieving site-specific modification of protein toxins. The second is to develop a prodrug feature that renders protein toxins remaining stealthy in blood for reduced side toxicity and improved EPR effect. The third is to develop a gelatinase activatable cell-penetration strategy for enhanced tumor targeting and cytoplasmic delivery. Of note, site-specific modification is a big challenge in protein drug research, especially for such a complicated, multifunctional protein delivery system. We successfully develop a protocol for constructing a macromolecular prodrug system with intein-mediated ligation synthesis. With an on-column process of purification and intein-mediated cleavage, the site-specific PEGylation then can be readily achieved by conjugation with the activated C-terminus, thus constructing a PEG-capped, cell-penetrating trichosanthin system with a gelatinase-cleavable linker that enables tumor-specific activation of cytoplasmic delivery. It provides a promising method to address the PEG dilemma for enhanced protein drug delivery, and importantly, a facile protocol for site-specific modification of such a class of protein drugs for improving their druggability and industrial translation.
Insights
This study introduces a novel prodrug system for protein toxins, overcoming PEGylation challenges in cancer therapy. The system enhances tumor targeting and cytoplasmic delivery, reducing side toxicity for improved cancer treatment.
Area of Science:
- Biotechnology
- Drug Delivery
- Cancer Therapy
Background:
- Poor tumor targeting and cytoplasmic delivery limit protein toxin efficacy in cancer therapy.
- Polyethylene glycol (PEG)ylation improves drug circulation but hinders tumor cell interaction, creating a delivery challenge.
- The 'PEG dilemma' necessitates strategies to maintain stealth circulation while enabling tumor-specific activation.
Purpose of the Study:
- To develop a site-selectively PEGylated, gelatinase-triggered, cell-penetrating trichosanthin protein delivery system.
- To create a prodrug feature for reduced toxicity and enhanced Enhanced Permeability and Retention (EPR) effect.
- To engineer a gelatinase-activatable strategy for improved tumor targeting and cytoplasmic delivery.
Main Methods:
- Inteintein-based ligation for site-specific protein toxin modification.
- Construction of a macromolecular prodrug system via intein-mediated ligation synthesis.
- On-column purification and cleavage for site-specific PEGylation via C-terminus conjugation.
Main Results:
- Successfully developed a protocol for constructing a multifunctional prodrug system.
- Achieved site-specific PEGylation, creating a PEG-capped, cell-penetrating trichosanthin system.
- Incorporated a gelatinase-cleavable linker for tumor-specific activation of cytoplasmic delivery.
Conclusions:
- The developed system addresses the PEG dilemma for enhanced protein drug delivery.
- Provides a facile protocol for site-specific modification of protein drugs, improving druggability.
- Offers a promising strategy for advanced cancer therapeutics with improved targeting and reduced side effects.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Tumor Immunotherapy
